@article{2f14542a00e34ac8b8da44fa5a551a0c,
title = "Transplant of organs from donors with positive SARS-CoV-2 nucleic acid testing: A report from the organ procurement and transplantation network ad hoc disease transmission advisory committee",
abstract = "Background: Decisions to transplant organs from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) nucleic acid test-positive (NAT+) donors must balance risk of donor-derived transmission events (DDTE) with the scarcity of available organs. Methods: Organ Procurement and Transplantation Network (OPTN) data were used to compare organ utilization and recipient outcomes between SARS-CoV-2 NAT+ and NAT– donors. NAT+ was defined by either a positive upper or lower respiratory tract (LRT) sample within 21 days of procurement. Potential DDTE were adjudicated by OPTN Disease Transmission Advisory Committee. Results: From May 27, 2021 (date of OTPN policy for required LRT testing of lung donors) to January 31, 2022, organs were recovered from 617 NAT+ donors from all OPTN regions and 53 of 57 (93%) organ procurement organizations. NAT+ donors were younger and had higher organ quality scores for kidney and liver. Organ utilization was lower for NAT+ donors compared to NAT– donors. A total of 1241 organs (776 kidneys, 316 livers, 106 hearts, 22 lungs, and 21 other) were transplanted from 514 NAT+ donors compared to 21 946 organs from 8853 NAT– donors. Medical urgency was lower for recipients of NAT+ liver and heart transplants. The median waitlist time was longer for liver recipients of NAT+ donors. The match run sequence number for final acceptor was higher for NAT+ donors for all organ types. Outcomes for hospital length of stay, 30-day mortality, and 30-day graft loss were similar for all organ types. No SARS-CoV-2 DDTE occurred in this interval. Conclusions: Transplantation of SARS-CoV-2 NAT+ donor organs appears safe for short-term outcomes of death and graft loss and ameliorates the organ shortage. Further study is required to assure comparable longer term outcomes. (Figure presented.).",
keywords = "COVID-19, SARS-CoV-2, donor, safety, transmission, transplantation, utilization",
author = "Goldman, {Jason D.} and Pouch, {Stephanie M.} and Woolley, {Ann E.} and Booker, {Sarah E.} and Jett, {Courtney T.} and Cole Fox and Berry, {Gerald J.} and Dunn, {Kelly E.} and Ho, {Chak Sum} and Michelle Kittleson and Lee, {Dong Heun} and Levine, {Deborah J.} and Marboe, {Charles C.} and Gary Marklin and Razonable, {Raymund R.} and Sarah Taimur and Te, {Helen S.} and Anesi, {Judith A.} and Fisher, {Cynthia E.} and Sellers, {Marty T.} and Trindade, {Anil J.} and Wood, {R. Patrick} and Lorenzo Zaffiri and Levi, {Marilyn E.} and David Klassen and Michaels, {Marian G.} and {La Hoz}, {Ricardo M.} and Lara Danziger-Isakov",
note = "Funding Information: This work was funded by the US Department of Health and Human Services, Health Resources and Services Administration (HRSA), and Health Systems Bureau, Division of Transplantation under contract number HHSH250201900001C, and was conducted under the auspices of the United Network for Organ Sharing (UNOS), the contractor for the Organ Procurement and Transplantation Network (OPTN). The interpretation and reporting of these data are the responsibility of the author(s) and in no way should be seen as an official policy of or interpretation by the OPTN or the US Government. Funding Information: This work was funded by the US Department of Health and Human Services, Health Resources and Services Administration (HRSA), and Health Systems Bureau, Division of Transplantation under contract number HHSH250201900001C, and was conducted under the auspices of the United Network for Organ Sharing (UNOS), the contractor for the Organ Procurement and Transplantation Network (OPTN). The interpretation and reporting of these data are the responsibility of the author(s) and in no way should be seen as an official policy of or interpretation by the OPTN or the US Government. Funding Information: Jason D. Goldman reported contracted research from Gilead, Eli Lilly, and Regeneron, grants from Merck (BARDA), and collaborative services agreements with Adaptive Biotechnologies, Monogram Biosciences, and Labcorp; and served as a consultant, speaker, or advisory board member for Gilead, Eli Lilly, GSK, and Karius. Raymund R. Razonable received research grants (funds to the institution) from Gilead, Renegeron, and Roche; served as member of the DSMB of Novartis; served as consultant to Glaxo‐Smith‐Kline, Merck, Roche; and served as Board of Director of the American Society of Transplantation. Helen S. Te served as a consultant for CVS Caremark and Precision BioSciences. Anil J. Trindade served on the Lung National Scientific Advisory Board for CareDx, Inc. He has received funding support from CareDx, Inc. and Veloxis Pharmaceuticals. All other authors declare they have no disclosures or conflicts of interest. Publisher Copyright: {\textcopyright} 2023 Wiley Periodicals LLC.",
year = "2023",
month = feb,
doi = "10.1111/tid.14013",
language = "English (US)",
volume = "25",
journal = "Transplant Infectious Disease",
issn = "1398-2273",
publisher = "Wiley-Blackwell",
number = "1",
}